- IMPACT, a multicenter pilot study of Alpha DaRT ® for newly diagnosed unresectable pancreatic canc

PAVmed (NASDAQ: PAVM - Get Free Report) and Alpha Tau Medical (NASDAQ: DRTS - Get Free Report) are b

HC Wainwright & Co. analyst Yi Chen maintains Alpha Tau Medical (NASDAQ:DRTS) with a Buy and

Alpha Tau Medical (NASDAQ:DRTS) reported quarterly losses of $(0.50) per share which missed the anal

JERUSALEM, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) (“Alpha Ta

HC Wainwright & Co. analyst Yi Chen reiterates Alpha Tau Medical (NASDAQ:DRTS) with a Buy and

Response RateAmong evaluable patients, treatment with Alpha DaRT plus pembrolizumab produced an obje

- Podium presentation at the American Head and Neck Society (AHNS) 12th International Conference on

Alpha Tau Medical Ltd. (NASDAQ: DRTS - Get Free Report) shares rose 7.1% on Friday. The company trad

Gainers Jasper Therapeutics (NASDAQ:JSPR) stock moved upwards by 19.2% to $0.92 during Friday's

HC Wainwright & Co. analyst Yi Chen reiterates Alpha Tau Medical (NASDAQ:DRTS) with a Buy and

- The ADMIRE study, by treating immunocompromised patients, builds on the momentum of Alpha Tau'

Alpha Tau Successfully Treats First Immunocompromised Patient with Recurrent Cutaneous Squamous Cell

AMPX, DRTS and BELFB have been added to the Zacks Rank #5 (Strong Sell) List on July 7, 2026.

DRTS, CANG and LAZ have been added to the Zacks Rank #5 (Strong Sell) List on July 2, 2026.

Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan

Alpha Tau Medical Ltd. (NASDAQ:DRTS, DRTSW)) ("Alpha Tau"), the developer of the innovative

Alpha Tau Successfully Treats First Recurrent Glioblastoma Patient Outside of the United States with

Alpha Tau Medical (DRTS) is pioneering localized alpha particle radiation for solid tumors, with str

- Following the pre-specified interim safety report and overwhelming demand from clinicians to treat

Alpha Tau Receives FDA Clearance to Complete Enrollment in REGAIN Trial and Add Two U.S. Sites; Earl

HC Wainwright & Co. analyst Yi Chen reiterates Alpha Tau Medical (NASDAQ:DRTS) with a Buy and

Barclays analyst Lukas Shumway maintains Alpha Tau Medical (NASDAQ:DRTS) with a Overweight and ra

Dow falls 296 points. Navitas Semi rises on partnership with Nvidia. Other gainers: ABVX, MMED, KELY

- Joint partnership leverages Alpha Tau's highly potent, localized alpha-radiation technology an

- Joint partnership leverages Alpha Tau's highly potent, localized alpha-radiation technology and To

HC Wainwright & Co. analyst Yi Chen reiterates Alpha Tau Medical (NASDAQ:DRTS) with a Buy and

- Results reinforce the potential feasibility and safety of Alpha DaRT as a one-time, minimally inva

- Results reinforce the potential feasibility and safety of Alpha DaRT as a one-time, minimally inva

Alpha Tau Medical NASDAQ: DRTS outlined a series of clinical and regulatory updates during the Lytha

Barclays analyst Lukas Shumway initiates coverage on Alpha Tau Medical (NASDAQ:DRTS) with a Overw

HC Wainwright & Co. analyst Yi Chen reiterates Alpha Tau Medical (NASDAQ:DRTS) with a Buy and

Piper Sandler analyst Jason Bednar maintains Alpha Tau Medical (NASDAQ:DRTS) with a Neutral and r

Alpha Tau Medical (NASDAQ:DRTS) reported quarterly losses of $(0.26) per share which missed the anal

- Groundbreaking interim results from U.S. REGAIN trial in recurrent glioblastoma demonstrate 100% l

JERUSALEM, May 18, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (

Ladenburg Thalmann analyst Jeff Cohen maintains Alpha Tau Medical (NASDAQ:DRTS) with a Buy and ra

HC Wainwright & Co. analyst Yi Chen maintains Alpha Tau Medical (NASDAQ:DRTS) with a Buy and

Shares of Alpha Tau Medical Ltd. (NASDAQ:DRTS) rose Monday after the company reported interim result

Alpha Tau Medical stock surged after interim glioblastoma data showed complete responses in two pati

Alpha Tau Medical NASDAQ: DRTS presented early clinical results from the first three patients treate

- Interim results from the first three brain cancer patients treated; two of whom demonstrated compl

By enabling two complementary delivery pathways - endoscopic ultrasound (EUS) and percutaneous - wit

- 100% local disease control rate achieved in evaluable patients in pooled analysis of two first-in-

- Abstract accepted at the American Society of Clinical Oncology (ASCO) Annual Meeting - the world&#

Alpha Tau Medical Ltd. (NASDAQ:DRTS, DRTSW)) ("Alpha Tau"), the developer of the innovative

ACAPELLA is the European multicenter clinical trial evaluating Alpha DaRT alpha-emitter radiotherape